GANX earnings

BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. This is

BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. "We are encouraged by the progress made in 2025, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. The promising impact GT-02287 has on the cau

BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. "The first quarter of 2025 marked yet another exciting milestone for Gain with the first administration of GT-02287, our lead drug candidate in development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation, to participants with Parkinson's disease in our ongoing Phase 1b study which began enrollment in early M

BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. "2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without GBA1 mutation," said Gene Mack, President and CEO

BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. "The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson's disease in patients with or without the GBA1 mutation. Data from our Phase 1 study for GT-02287 presented recently at both the International Congress of Parkinson's Disease and Movement

Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson's Disease Patients Event Will Be Held on Monday, September 30, 2024, at 8:30 am ET BETHESDA, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a webinar to discuss data from the Phase 1 study of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson's disease, recently presented in a late-breaker at the International Congress

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open. Participants can join the conference call through the News and Events section of the Company website at https://www.gaintherapeutics.com/investors-media/news-events. A recorded version and transcript of the call will be archived and available for replay in the News and Even

BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended March 31, 2024, and provides a corporate update. Corporate Highlights from Q1 2024 to Date Announced Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287Strengthened management team with appointment of Gene Mack as Chief Financial Officer and Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerPresented data at AD/PD 2024 demonstrating m

Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson's Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief Executive Officer and Appointed him to the Board of Directors $25.7 Million in Cash and Cash Equivalents and Marketable Securities as of September 30, 2022 Provides Strong Financial Foundation and Extends Cash Runway into Q2 2024 BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allos

BETHESDA, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its financial results for the second quarter ended June 30, 2022, and highlighted recent corporate progress. "We move into the second half of 2022 having made tangible progress across our pipeline," said Eric Richman, Chief Executive Officer of Gain Therapeutics. "We continued to expand the body of positive preclinical data on our lead programs in Parkinson's disease and Gau

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson's Disease and Gaucher's Disease. $34.34 Million in Cash as of March 31, 2022, Provides Runway into Second half of 2023 and a Strong Cash Position to Transition the Company's Lead Program into Clinical Trials BETHESDA, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its

$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company's lead program into clinical trials ---Compelling preclinical data presented on lead program GBA1 Parkinson's Disease at multiple scientific conferences supports transition to clinical stage company with FIH trial by year end --- Entered into multi-target deal with Zentalis Pharmaceuticals to identify novel small molecules for oncology indications  BETHESDA, Md., March 24, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company focused on identifying and optimizing allosteric binding sites t

Data from Patient-Derived iPSC Study Evaluating STAR Compounds Show Positive Effects on Disease Onset and Progression; Full Data Presented at MJFF's Parkinson's Disease Therapeutics Conference--- Appoints Matthias Alder as Chief Operating Officer and Appoints 5 Members to Newly Formed Scientific Advisory Board---$40.98 Million in Cash as of September 30, 2021, Provides Runway into Second half of 2023 and a Strong Cash Position to Transition the Company's Lead Program into Clinical Trials BETHESDA, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company focused on identifying and optimizing allosteric binding sites th